Amgen wins biosimilars case against Apotex at Federal Circuit

06-07-2016

Amgen wins biosimilars case against Apotex at Federal Circuit

Icon Craft Studio / Shutterstock.com

The US Court of Appeals for the Federal Circuit ruled yesterday in the Amgen v Apotex case that bisoimilars companies must always notify brand name rivals 180 days before launching their products.


Amgen, Apotex, Neulasta, US Court of Appeals for the Federal Circuit, BPCIA, patent, biosimilars

LSIPR